KORU Medical Systems (NASDAQ:KRMD) Issues Earnings Results

KORU Medical Systems (NASDAQ:KRMD) issued its quarterly earnings results on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01, Zacks reports. The firm had revenue of $10.90 million for the quarter, compared to the consensus estimate of $10.90 million. KORU Medical Systems had a negative net margin of 6.41% and a negative return on equity of 15.90%.

Here are the key takeaways from KORU Medical Systems’ conference call:

• CEO Linda Tharby announced her planned retirement effective June 30, 2026, with CCO Adam Kalbermatten named President on March 15 and set to become CEO on July 1, and Linda remaining as an advisor through year-end.
• KORU delivered strong financials with Q4 revenue of $10.9M (+23% YoY), full-year revenue of $41.1M (+22%), positive adjusted EBITDA (~$0.6M) and positive operating cash flow, ending 2025 with $8.9M cash.
• International momentum accelerated (Q4 international growth ~71%, full-year ~80%), and EU MDR clearance for the Freedom60 prefilled-syringe compatibility enables shipments into Europe and targets an estimated $50M addressable market.
• KORU is expanding beyond IG — received 510(k) clearance for RYSTIGGO (entry into infusion clinics), has 9 drugs on label and 9 active pipeline collaborations (including near-term vancomycin, deferoxamine, Phesgo), and guided 2026 revenue of $47.5–$50M with positive adjusted EBITDA and full-year positive cash flow.
• Headwinds include modest gross margin pressure from higher material costs, tariffs and geographic mix, a 30% decline in PST (pharma services & trials) revenue due to milestone timing, and a relatively modest year-end cash balance that could leave limited downside cushion if expected milestones or prefill conversions slip.

KORU Medical Systems Stock Performance

Shares of NASDAQ:KRMD opened at $4.28 on Monday. KORU Medical Systems has a 52-week low of $1.86 and a 52-week high of $6.61. The business’s 50 day simple moving average is $5.10 and its two-hundred day simple moving average is $4.80. The firm has a market cap of $198.46 million, a P/E ratio of -71.33 and a beta of 0.47.

Hedge Funds Weigh In On KORU Medical Systems

Institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC lifted its holdings in shares of KORU Medical Systems by 927.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 77,280 shares of the company’s stock worth $196,000 after purchasing an additional 69,758 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in KORU Medical Systems by 189.5% during the first quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock worth $617,000 after buying an additional 158,914 shares during the last quarter. Jane Street Group LLC raised its holdings in KORU Medical Systems by 136.7% during the first quarter. Jane Street Group LLC now owns 163,137 shares of the company’s stock worth $414,000 after buying an additional 94,214 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of KORU Medical Systems in the first quarter valued at $63,000. Finally, Geode Capital Management LLC lifted its stake in shares of KORU Medical Systems by 101.3% in the second quarter. Geode Capital Management LLC now owns 997,147 shares of the company’s stock valued at $3,571,000 after buying an additional 501,875 shares in the last quarter. 58.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Craig Hallum reaffirmed a “buy” rating and set a $7.00 target price on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Lake Street Capital increased their price target on KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. B. Riley Financial lifted their price objective on shares of KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of KORU Medical Systems from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.50.

Key Headlines Impacting KORU Medical Systems

Here are the key news stories impacting KORU Medical Systems this week:

• Positive Sentiment: B. Riley raised its price target to $8.00 and maintained a “buy” rating, implying roughly an 87% upside from the current price — a meaningful vote of confidence from a major dealer. Benzinga
• Positive Sentiment: Canaccord Genuity reaffirmed its “buy” rating and set a $6.00 target (?40% upside), adding further analyst support for upside to the stock. Benzinga
• Positive Sentiment: KORU received EU MDR certification for its Freedom60® infusion pump with prefilled syringe compatibility — clear regulatory progress that should aid European commercialization and recurring revenue potential. Las Vegas Sun
• Positive Sentiment: Q4 2025 results beat EPS expectations (loss of $0.01 vs. -$0.02 est.), reported ~20% revenue growth and positive adjusted EBITDA; management also initiated FY2026 guidance with revenue of $47.5M–$50.0M (roughly in line with consensus ~ $48.8M). These operational improvements support medium-term growth prospects. Business Wire – Q4 & Guidance
• Neutral Sentiment: Analysts and the company provided forward revenue guidance but EPS guidance detail was not clearly disclosed in public summaries; revenue range is encouraging but leaves some near-term visibility questions. Q4 Press Release / Slide Deck
• Negative Sentiment: KORU announced a CEO transition: long-time CEO Linda Tharby will retire June 30 and the board appointed Adam Kalberma as successor. Leadership changes introduce short-term execution risk and can pressure the stock until the market judges the new CEO. Business Wire – CEO Transition
• Negative Sentiment: Despite positives, KRMD still shows a negative net margin and negative ROE; valuation and profitability concerns may keep selling pressure, which likely explains why the stock is trading lower even after upgrades and regulatory wins.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.